Literature DB >> 11126356

Cyclin D1 suppresses retinoblastoma protein-mediated inhibition of TAFII250 kinase activity.

J L Siegert1, J J Rushton, W R Sellers, W G Kaelin, P D Robbins.   

Abstract

The retinoblastoma tumor suppressor protein has been shown to bind directly and inhibit a transcriptionally-important amino-terminal kinase domain of TATA-binding protein-associated factor TAFII250. Cyclin D1 also is able to associate with the amino terminus of TAFII250 in a region very similar to or overlapping the Rb-binding site. In this study, we have examined whether cyclin D1 affects the functional interaction between Rb and TAFII250. We observed that when cyclin D1 is coincubated with Rb and TAFII250, the ability of Rb to inhibit TAFII250 kinase activity is effectively blocked. However, cyclin D1 by itself has no apparent effect on TAFII250 kinase activity. We further found that the Rb-related protein p107 can inhibit TAFII250 kinase activity, and this inhibition is likewise alleviated by cyclin D1. Cyclin D1 prevents the kinase-inhibitory effect of an Rb mutant unable to bind to D-type cyclins, indicating that it is acting through its association with TAFII250 and not with Rb. However, we found no evidence of TAFII250-binding competition between Rb and cyclin D1 in vitro. The adenovirus E1A protein, which also binds to both Rb and TAFII250, exhibited a suppressive effect on Rb-mediated kinase inhibition similar to that seen with cyclin D1. Our results suggest a novel means by which cyclin D1 may be able to independently regulate the activity of Rb.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11126356     DOI: 10.1038/sj.onc.1203966

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  Transcriptional regulation by a DNA-associated form of cyclin D1.

Authors:  Frédéric Bienvenu; Benjamin Barré; Sandrine Giraud; Sylvie Avril; Olivier Coqueret
Journal:  Mol Biol Cell       Date:  2005-01-19       Impact factor: 4.138

2.  Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.

Authors:  Ryan D Morin; Karen Mungall; Erin Pleasance; Andrew J Mungall; Rodrigo Goya; Ryan D Huff; David W Scott; Jiarui Ding; Andrew Roth; Readman Chiu; Richard D Corbett; Fong Chun Chan; Maria Mendez-Lago; Diane L Trinh; Madison Bolger-Munro; Greg Taylor; Alireza Hadj Khodabakhshi; Susana Ben-Neriah; Julia Pon; Barbara Meissner; Bruce Woolcock; Noushin Farnoud; Sanja Rogic; Emilia L Lim; Nathalie A Johnson; Sohrab Shah; Steven Jones; Christian Steidl; Robert Holt; Inanc Birol; Richard Moore; Joseph M Connors; Randy D Gascoyne; Marco A Marra
Journal:  Blood       Date:  2013-05-22       Impact factor: 22.113

Review 3.  Cyclin D as a therapeutic target in cancer.

Authors:  Elizabeth A Musgrove; C Elizabeth Caldon; Jane Barraclough; Andrew Stone; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2011-07-07       Impact factor: 60.716

4.  TAF1 differentially enhances androgen receptor transcriptional activity via its N-terminal kinase and ubiquitin-activating and -conjugating domains.

Authors:  Peyman Tavassoli; Latif A Wafa; Helen Cheng; Amina Zoubeidi; Ladan Fazli; Martin Gleave; Robert Snoek; Paul S Rennie
Journal:  Mol Endocrinol       Date:  2010-02-24

5.  Gene expression profiling of monkeypox virus-infected cells reveals novel interfaces for host-virus interactions.

Authors:  Abdulnaser Alkhalil; Rasha Hammamieh; Justin Hardick; Mohamed Ait Ichou; Marti Jett; Sofi Ibrahim
Journal:  Virol J       Date:  2010-07-28       Impact factor: 4.099

6.  GCNF-dependent activation of cyclin D1 expression via repression of Mir302a during ESC differentiation.

Authors:  Hongran Wang; Xiaohong Wang; Trevor K Archer; Thomas P Zwaka; Austin J Cooney
Journal:  Stem Cells       Date:  2014-06       Impact factor: 6.277

7.  Effects of altered expression and localization of cyclophilin A on differentiation of p19 embryonic carcinoma cells.

Authors:  Robert Chiu; Osvaldo Rey; Jun-Qi Zheng; Jeffery L Twiss; Jun Song; Shen Pang; Kazunari K Yokoyama
Journal:  Cell Mol Neurobiol       Date:  2003-12       Impact factor: 5.046

8.  Epstein-Barr virus nuclear antigen 3C facilitates G1-S transition by stabilizing and enhancing the function of cyclin D1.

Authors:  Abhik Saha; Sabyasachi Halder; Santosh K Upadhyay; Jie Lu; Pankaj Kumar; Masanao Murakami; Qiliang Cai; Erle S Robertson
Journal:  PLoS Pathog       Date:  2011-02-10       Impact factor: 6.823

9.  AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasis.

Authors:  Jino Park; Michaela Schlederer; Martin Schreiber; Ryan Ice; Olaf Merkel; Martin Bilban; Sebastian Hofbauer; Soojin Kim; Joseph Addison; Jie Zou; Chunyan Ji; Silvia T Bunting; Zhengqi Wang; Menachem Shoham; Gang Huang; Zsuzsanna Bago-Horvath; Laura F Gibson; Yon Rojanasakul; Scot Remick; Alexey Ivanov; Elena Pugacheva; Kevin D Bunting; Richard Moriggl; Lukas Kenner; William Tse
Journal:  Oncotarget       Date:  2015-08-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.